Globally, cerebrovascular diseases have become one of the major public health issues, with China facing particularly severe challenges. China bears a heavy burden of cerebrovascular diseases, ranking first in causes of death, and the prevalence rate is continuously climbing, putting immense economic pressure on patients and society. According to data from the 'China Health and Wellness Statistical Yearbook', the inpatient medical costs for cerebrovascular disease patients have been increasing year by year, reaching 762 billion yuan in 2021. During the diagnosis and treatment process, new drug research and development costs are high, the cycle is long, some drug production capacity is insufficient, treatment effects are limited, and interventional surgeries are complex with a shortage of professional talent, which restricts the development of diagnostic and treatment technologies. However, the Chinese government encourages the development of new productive forces and promotes high-quality economic development, which also brings new development opportunities to the cerebrovascular disease industry. The application of new productive forces, such as artificial intelligence-assisted diagnosis and telemedicine, is improving diagnostic accuracy and treatment efficiency, providing personalized treatment plans for patients, and pushing the industry into a new era of precision medicine and efficient management, showing great potential and value.
Frost & Sullivan (Frost & Sullivan, abbreviated as 'Frost & Sullivan') in collaboration with the Chinese Stroke Society, wrote the 'White Paper on the Current Situation and Development of China's Cerebrovascular Disease Industry' (hereinafter referred to as 'the White Paper'), which conducts an in-depth analysis of the current situation of cerebrovascular disease diagnosis and treatment in China by interviewing clinical and industry experts and synthesizing the latest industry trends. The White Paper identifies 30 clinical pain points with innovative transformation value, detailing the current status, difficulties, and potential solutions to these pain points, aiming to provide a scientific reference for all sectors involved in industry, academia, and research in choosing directions for medical innovation, and to jointly write a new chapter in the development of China's cerebrovascular disease industry.
